Orphalan Launches Groundbreaking Wilson Disease Treatment in China
Strategic partnership with Kyuan Xinhai Medical Products Trade Co., Ltd to enhance access to Wilson's disease treatment for patients
Orphalan, a leading name in orphan drug development, achieves a remarkable milestone by introducing its treatment for Wilson's disease, "Ke Pei Ou" (???®), in China. This pivotal achievement positions Orphalan as the first European pharmaceutical entity to unveil an orphan drug in the Chinese Wilson Disease sector, symbolizing a major progression in the realm of global rare disease management.
This game-changing launch is fueled by a strategic alliance with SPH Kyuan Trade, a top-tier pharmaceutical distributor in China and a subsidiary of the renowned Shanghai Pharma Group. Together, they strive to facilitate broad patient access to this vital therapy.
A New Era for Patients with Wilson's Disease
Wilson's disease is a rare and life-threatening genetic condition that impairs the body's capacity to rid itself of excess copper, often leading to serious neurological and liver issues. Previously, penicillamine was the standard treatment; however, due to its side effects, many patients faced restricted options—until now.
Orphalan's trientine tetrahydrochloride, branded as "Ke Pei Ou" (???®), is the first trientine-based therapy authorized by the NMPA (National Medical Products Administration) in China. Having been made available in over 20 markets globally, under names like Cuprior® in regions such as the EU, UK, and others, this treatment is poised to transform the lives of numerous patients in China.
Now available under the name "Ke Pei Ou" (???®), this therapy offers new hope to countless patients who lacked viable alternatives previously.
Strengthening Orphalan's Commitment in China
Understanding the crucial role China plays in its broader mission, Orphalan has set up a local entity in Shanghai and appointed Ms. Grace Li as General Manager. With a dedicated team of scientific and medical professionals, Ms. Li will lead initiatives to:
- Engage healthcare leaders to provide access to the latest insights in Wilson's disease management.
- Promote medical knowledge and education, ensuring informed options for physicians and patients alike.
- Enhance Orphalan's presence within the healthcare landscape of China for sustained success with "Ke Pei Ou" (???®).
A Defining Milestone for Global Expansion
This landmark achievement is part of Orphalan's commitment to furthering treatments for rare diseases on a global scale. By entering the demanding and regulated Chinese pharmaceutical market, Orphalan solidifies its presence as a leader in orphan drug innovation and accessibility to care.
Dr. Naseem Amin, CEO of Orphalan, emphasized the importance of this advancement:
"This expansion represents a breakthrough for rare disease patients in China. Our partnership with SPH Kyuan Trade is a significant milestone in Orphalan's evolution. We are not merely introducing a medication—our aim is to transform care accessibility for those in need. This launch underscores our dedication to providing innovative therapies worldwide."
As Orphalan continues to break barriers in scientific progress and therapeutic solutions, its commitment remains steadfast in ensuring that patients in China have access to the latest developments in Wilson's disease therapy.
With "Ke Pei Ou" (???®) now in Chinese markets, Orphalan is establishing a new benchmark for what can be achieved in orphan drug innovation and global healthcare access.
About Orphalan
Orphalan stands as an international pharmaceutical company focused on orphan drugs, headquartered in Paris. Established in 2011, the company dedicates itself to creating pioneering therapies for individuals afflicted by rare and debilitating conditions. Committed to collaborative efforts with the rare disease and scientific communities, Orphalan aims to advance evidence-based treatments for unaddressed needs. The trientine tetrahydrochloride product, approved for Wilson's disease therapy, is currently available in over 20 territories, branded as Cuprior® in the EU and the UK, Cuvrior® in the United States, and as "Ke Pei Ou" in China.
Frequently Asked Questions
What is Orphalan's recent achievement related to Wilson's disease?
Orphalan has launched its Wilson's disease treatment, "Ke Pei Ou" (???®), in China, marking a significant milestone in orphan drug access.
How does the partnership with SPH Kyuan Trade enhance the treatment availability?
The partnership facilitates broader distribution and access to the treatment for Wilson's disease patients in China.
What sets "Ke Pei Ou" apart from previous treatments?
It is the first trientine-based therapy approved in China, offering an alternative for patients intolerant to traditional treatments like penicillamine.
Who is overseeing Orphalan's operations in China?
Ms. Grace Li has been appointed as General Manager to lead Orphalan's initiatives in the Chinese market.
What is Orphalan's overall mission?
The company's mission focuses on advancing innovative therapies for rare diseases while ensuring accessible treatment options globally.
